Physician profile
Phyllis S Kim
NPI 1427375369
$775.09
in general payments reported to CMS, 2019-2025
13 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.55 · 2021: $22.93 · 2022: $75.12 · 2023: $109 · 2024: $91.11 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $235.62 | 2021-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $106.33 | 2019-2025 | Calquence |
| Merck Sharp & Dohme LLC | $85.00 | 2024-2025 | Keytruda |
| Janssen Biotech, INC. | $61.99 | 2025 | Carvykti, Talvey, Darzalex |
| Alexion Pharmaceuticals, INC. | $49.60 | 2024-2025 | Ultomiris |
| Adc Therapeutics America, INC. | $49.51 | 2023-2025 | |
| Eisai INC. | $38.48 | 2025 | |
| Genmab U.S., INC. | $30.17 | 2025 | Epkinly |
| Dendreon Pharmaceuticals LLC | $29.91 | 2025 | Provenge |
| Genentech USA, INC. | $24.22 | 2025 | Columvi |
| Novartis Pharmaceuticals Corporation | $23.59 | 2025 | |
| Genzyme Corporation | $23.51 | 2024 | |
| Pfizer INC. | $17.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.